• Wednesday, October 20, 2021 @ 12:00 am


Santhera is two major steps closer to achieving our global peak sales forecasts of CHF 550+ mn for vamorolone in DMD alone, including: 1) positive pivotal “VISION-DMD” 24-week trial results, and 2) securing sufficient funding to mid-2022. Santhera provides substantial equity upside, while vamorolone in DMD has been largely de-risked.

Key catalysts include:

  • Vamorolone pivotal “VISION-DMD” 48-week trial results (Q4 2021)
  • Vamorolone US DMD filing (Q1 2022)
  • Vamorolone EU DMD filing (Q2 2022)

To the Santhera Valuation Report

You may also be interested in